Wells Pharmacy Recalls Testosterone Pellets Due to Potency Issues
Wells Pharmacy Network is recalling Testosterone 12.5 mg Pellets because they were found to be superpotent or subpotent.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which indicates a low risk of adverse health consequences, aligning with the Moderate severity score for minor labeling or potency errors without reported harm.
Plain-English summary
Wells Pharmacy Network, LLC is recalling Testosterone 12.5 mg Pellets. The recall was initiated because the product was identified as superpotent and subpotent, meaning the drug concentration did not meet standard requirements.
The affected product consists of 322 pellets. The specific lot number is 08052016@3, and the beyond-use date is 02/01/2017. The product was distributed in the U.S.
Consumers who have this product should stop using it and contact their healthcare provider or the recalling firm for instructions on disposal or replacement.
The recalled product
- Product
- Testosterone 12.5 mg Pellet, Compounded by: Wells Pharmacy Network
- Manufacturer
- Wells Pharmacy Network, LLC
- Hazard
- Affected units
- 322
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot Number 08052016@3
- BUD 02/01/2017
Distribution
Distribution scope not specified by the agency.
Part of a larger recall action
This product is one of 7 recalled by Wells Pharmacy Network, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 7 products in this recall →Related recalls
Same manufacturer · Wells Pharmacy Network, LLC
See all →- SevereWells Pharmacy Recalls Injectable Compounds Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- SevereWells Pharmacy Recalls Compounded Chorionic Gonadotropin Injectable Kits
FDA (Drugs) · 2017-01-11
- SevereWells Pharmacy Recalls Compounded Injectable Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- SevereWells Pharmacy Recalls Trimix with Atropine Injectable Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- SevereWells Pharmacy Recalls Testosterone Cypionate Injectable Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
Same hazard · potency issues
See all →- SevereIngenus Recalls Irinotecan Hydrochloride Injection Due to Potency Issues
FDA (Drugs) · 2018-07-11
- LowApotex Recalls Aripiprazole Tablets Due to Potential Potency Issues
FDA (Drugs) · 2017-02-15
- SevereWells Pharmacy Recalls Testosterone and Anastrazole Pellets Due to Potency Issues
FDA (Drugs) · 2016-11-16